Literature DB >> 28642139

Clinical characteristics and epidemiology of sepsis in the neonatal intensive care unit in the era of multi-drug resistant organisms: A retrospective review.

Dawood Yusef1, Tala Shalakhti2, Samah Awad3, Hana'a Algharaibeh3, Wasim Khasawneh4.   

Abstract

BACKGROUND: Sepsis in the neonatal intensive care unit (NICU) remains one of the most significant causes of morbidity and mortality, especially for preterm newborns. Multi-drug resistant organisms (MDROs) are emerging as important pathogens that cause neonatal sepsis in NICU. Therefore, studying the epidemiology, clinical features, and outcome caused by MDROs vs. non-MDROs, and identifying risk factors that may predispose patients to sepsis by MDROs are important.
METHODS: Episodes of blood culture-proven sepsis (age: 0-90 days) in the NICU at our institution from January 2012 to December 2015 were retrospectively reviewed. Collected data included demographics, signs at time of sepsis, laboratory values, microbiologic results, and final outcome. We compared clinical and laboratory data and final outcome for patients with sepsis due to MDROs vs. non-MDROs. Multivariate analysis was performed on variables with a P value of <0.05 from univariate analysis.
RESULTS: Sixty-eight episodes of sepsis (ages 0-54 days, median 7 days; 34 female; 81% premature) were caused by Gram-negative bacteria (n = 42; 62%), Gram-positive bacteria (n = 21; 31%), or Candida (n = 5; 7%). The most common organisms that were isolated were Acinetobacter baumannii (27%), Klebsiella pneumoniae (22%), coagulase-negative staphylococcus (CoNS) (18%), group B streptococcus (10%), and Escherichia coli (6%). Compared with non-MDROs (n = 16; 31%, excluding CoNS and Candida), MDROs (n = 35; 69%) were associated with higher mortality (P = 0.002) and more delay in providing targeted antimicrobial therapy (P = 0.002) (based on antimicrobial susceptibility tests). Sepsis due to the most resistant organisms (A. baumannii and K. pneumoniae Carbapenemase [KPC]-producing bacteria, n = 20; 39%) was associated with higher mortality (P = 0.001) and significantly associated with exposure to carbapenem and vancomycin before onset of sepsis (cases exposed = 13/20; 65%, P < 0.001).
CONCLUSION: MDROs are the most common cause of sepsis at our NICU and are associated with higher mortality compared with non-MDROs. Previous exposure to carbapenem and vancomycin was associated with sepsis caused by the most resistant organisms.
Copyright © 2017. Published by Elsevier B.V.

Entities:  

Keywords:  multiple antibacterial drug resistance; neonatal intensive care unit; sepsis

Mesh:

Year:  2017        PMID: 28642139     DOI: 10.1016/j.pedneo.2017.06.001

Source DB:  PubMed          Journal:  Pediatr Neonatol        ISSN: 1875-9572            Impact factor:   2.083


  25 in total

1.  Community-acquired serious bacterial infections in the first 90 days of life: a revisit in the era of multi-drug-resistant organisms.

Authors:  Dawood Yusef; Tamara Jahmani; Sajeda Kailani; Rawan Al-Rawi; Wasim Khasawneh; Miral Almomani
Journal:  World J Pediatr       Date:  2019-06-22       Impact factor: 2.764

2.  Vancomycin Is Protective in a Neonatal Mouse Model of Staphylococcus epidermidis-Potentiated Hypoxic-Ischemic Brain Injury.

Authors:  Jacqueline C Y Lai; Pernilla Svedin; C Joakim Ek; Amin Mottahedin; Xiaoyang Wang; Ofer Levy; Andrew Currie; Tobias Strunk; Carina Mallard
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

3.  Contemporary Trends in Global Mortality of Sepsis Among Young Infants Less Than 90 Days: A Systematic Review and Meta-Analysis.

Authors:  Ming Ying Gan; Wen Li Lee; Bei Jun Yap; Shu Ting Tammie Seethor; Rachel G Greenberg; Jen Heng Pek; Bobby Tan; Christoph Paul Vincent Hornik; Jan Hau Lee; Shu-Ling Chong
Journal:  Front Pediatr       Date:  2022-06-03       Impact factor: 3.569

4.  Gene expression analysis for pneumonia caused by Gram-positive bacterial infection.

Authors:  Rufu Jia; Jingyan Yang; Ying Cui; Dongjie Guo; Tiejun Li
Journal:  Exp Ther Med       Date:  2018-02-28       Impact factor: 2.447

Review 5.  Acinetobacter Infections in Neonates.

Authors:  Raffaele Zarrilli; Maria Bagattini; Eliana Pia Esposito; Maria Triassi
Journal:  Curr Infect Dis Rep       Date:  2018-10-10       Impact factor: 3.725

6.  Neonatal Sepsis, Antibiotic Susceptibility Pattern, and Treatment Outcomes among Neonates Treated in Two Tertiary Care Hospitals of Yangon, Myanmar from 2017 to 2019.

Authors:  Nan Aye Thida Oo; Jeffrey K Edwards; Prajjwal Pyakurel; Pruthu Thekkur; Thae Maung Maung; Nant San San Aye; Hla Myat Nwe
Journal:  Trop Med Infect Dis       Date:  2021-04-28

7.  Cuminaldehyde potentiates the antimicrobial actions of ciprofloxacin against Staphylococcus aureus and Escherichia coli.

Authors:  Valério Monteiro-Neto; Cláudio D de Souza; Laoane F Gonzaga; Bruna C da Silveira; Nágila C F Sousa; Jaqueline P Pontes; Deivid M Santos; Wanessa C Martins; Jorge F V Pessoa; Alexsander R Carvalho Júnior; Viviane S S Almeida; Natália M T de Oliveira; Thayla S de Araújo; Daniele Maria-Ferreira; Saulo J F Mendes; Thiago A F Ferro; Elizabeth S Fernandes
Journal:  PLoS One       Date:  2020-05-14       Impact factor: 3.240

8.  Bacteriological profile and antibiotic susceptibility of neonatal sepsis in neonatal intensive care unit of a tertiary hospital in Nepal.

Authors:  Bhishma Pokhrel; Tapendra Koirala; Ganesh Shah; Suchita Joshi; Pinky Baral
Journal:  BMC Pediatr       Date:  2018-06-27       Impact factor: 2.125

9.  A Systemic Review and Meta-analysis of the Leading Pathogens Causing Neonatal Sepsis in Developing Countries.

Authors:  Desalegne Amare Zelellw; Getenet Dessie; Endalkachew Worku Mengesha; Melashu Balew Shiferaw; Masresha Mela Merhaba; Solomon Emishaw
Journal:  Biomed Res Int       Date:  2021-06-05       Impact factor: 3.411

10.  Differences in clinical characteristics of early- and late-onset neonatal sepsis caused by Klebsiella pneumoniae.

Authors:  Ting You; Han Zhang; Lu Guo; Ke-Ran Ling; Xiao-Yu Hu; Lu-Quan Li
Journal:  Int J Immunopathol Pharmacol       Date:  2020 Jan-Dec       Impact factor: 3.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.